BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is set to provide a corporate update on its planned Phase 3b clinical trial for NurOwn, an innovative cell therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS). The announcement was made on October 7, 2024.
The update will be delivered by Chaim Lebovits, President and CEO of BrainStorm, during a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 15, 2024, at 9:30 a.m. ET. The session, moderated by Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, will offer insights into the design and objectives of the upcoming trial.
About NurOwn
The NurOwn technology platform utilizes autologous mesenchymal stem cells (MSCs) that are induced to secrete neurotrophic factors (MSC-NTF cells). This approach targets critical disease pathways involved in neurodegenerative disorders. The MSC-NTF cells are harvested from each individual ALS patient and manufactured through a proprietary process. The lead program for NurOwn is focused on ALS.
BrainStorm's commitment to ALS research is reflected in extensive preclinical studies and a series of clinical trials, all of which have been published in peer-reviewed journals. These studies have yielded valuable insights into the underlying pathology of ALS, as well as disease progression and potential therapeutic interventions.
Clinical Insights from NurOwn Program
Data from the NurOwn clinical program has facilitated in-depth analyses of various aspects of ALS, including the quantification of the Floor Effect, longitudinal evaluation of pre-specified biomarkers across a 20-week period, and pharmacogenomic analysis of clinical outcomes. These analyses offer promise for the development of future treatments for ALS.
